Clinical Trials Logo

Filter by:
NCT ID: NCT05364931 Completed - Clinical trials for Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

A Study to Evaluate the Safety and Efficacy of Cotadutide Given by Subcutaneous Injection in Adult Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

PROXYMO-ADV
Start date: July 14, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of cotadutide in participants with non-cirrhotic NASH with fibrosis.

NCT ID: NCT05364905 Completed - Endometrial Cancer Clinical Trials

Patients Characteristics, Treatment Pattern & Outcomes of Patients With Advanced, Recurrent or Metastatic Endometrial Carcinoma

ENDOVIE
Start date: May 9, 2022
Phase:
Study type: Observational

This is a national observational retrospective multi-site chart review study of patients with advanced, recurrent or metastatic endometrial carcinoma.

NCT ID: NCT05364554 Completed - Plaque Psoriasis Clinical Trials

A Long-term Extension Study of JNJ-77242113 in Participants With Moderate-to-Severe Plaque Psoriasis

FRONTIER 2
Start date: June 10, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate long-term clinical response of JNJ-77242113 treatment in participants with moderate-to-severe plaque psoriasis.

NCT ID: NCT05362656 Completed - Atrial Fibrillation Clinical Trials

AutoMatic disPERsion Tagging Function Preliminary Evaluation

AMPERE
Start date: May 29, 2022
Phase: N/A
Study type: Interventional

Interventional, prospective, non-randomized, single-center, non-controlled clinical investigation as part of the premarket clinical evaluation of VX1+ medical device, aiming to verify that VX1+ in bidirectional configuration with auto-tagging function is both ergonomic and reliable for dispersed electrograms detection and automatic tagging on 3D-map in real-time.

NCT ID: NCT05362604 Completed - Clinical trials for Antenatal Management of the Fetal Gastrointestinal Atresia

Prenatal Diagnosis of the Fetal Esophageal or Intestinal Atresia

DANATRESIA
Start date: April 1, 2021
Phase:
Study type: Observational

Aim- to investigate how prenatal diagnosis of fetal esophageal or intestinal atresia impacts obstetric and neonatal outcomes. Methods- This was a retrospective cohort study at a single center. The study population comprised 51 consecutive pregnancies, including 29 mothers (57%) and their fetuses affected by prenatally diagnosed fetal esophageal or intestinal atresia, and 22 mothers (43%) and their babies with postnatally diagnosed fetal esophageal or intestinal atresia.

NCT ID: NCT05362006 Completed - Multiple Sclerosis Clinical Trials

Exopulse Mollii Suit, Spasticity & Tissue Oxygenation

ENNOX
Start date: March 1, 2022
Phase: N/A
Study type: Interventional

Spasticity is a frequent and debilitating symptom in patients with multiple sclerosis (MS). Sustained contractile activity, such as that observed in spastic muscles, could reduce the capillary density and induce important changes in the muscular microcirculation, leading to oxidative changes within the muscular tissue. Such changes reflect altered aerobic metabolism and impaired mitochondrial function. The available therapeutic strategies for treating spasticity and related symptoms are usually faced with limited efficacy and numerous side effects. For these reasons, non-invasive stimulation techniques, namely transcutaneous stimulation by means of Exopulse Mollii suit, might be of help in this context.

NCT ID: NCT05361928 Completed - Muscle Injury Clinical Trials

IS ElastomEtry Useful in Muscle Lesion evaluaTion-REPROducibility Study

ISEULT-Repro
Start date: January 10, 2021
Phase:
Study type: Observational

Our objective is to evaluate the inter and intra observer reproducibility of the measure of elasticity using Acoustic Radiation Force Impulse (ARFI) ultrasonography of mucles of patients with and without hamstring injury. 76 patients will be evaluated cross sectionally twice by two ultrasonographists.

NCT ID: NCT05361577 Completed - Clinical trials for Fibromyalgia, Primary

Exopulse Mollii Suit and Fibromyalgia

EXOFIB
Start date: March 1, 2022
Phase: N/A
Study type: Interventional

Fibromyalgia is a debilitating pain condition that is characterized by the chronic occurrence of pain affecting the musculoskeletal system, a sensitivity to pressure stimuli, and a low threshold to noxious stimuli. The topography of pain is widespread, although it could be more pronounced in some bodily regions. Besides pain, patients suffer from a wide range of symptoms, including fatigue, anxiety and depression manifestations, and altered quality of life. Facing these debilitating symptoms, the available therapeutic strategies for treating pain and associated manifestations are usually faced with limited efficacy and numerous side effects. For these reasons, non-invasive stimulation techniques, namely transcutaneous stimulation by means of Exopulse Mollii suit, might be of help in this context. The investigators designed a randomized sham controlled double-blind trial to demonstrate the improvement of pain, quality of life, fatigue and mood in adult patients with fibromyalgia following a 2-week intervention of "active" versus "sham" Exopulse Mollii suit. A 2-week washout period should be enough to prevent a potential carry over effect. After this phase (phase 1), a second open label phase (phase 2) will be proposed for patients to understand the effects of Exopulse Mollii suit employed for 4 weeks (7 sessions per week) on the studied outcomes.

NCT ID: NCT05360862 Completed - Clinical trials for COVID-19 Acute Respiratory Distress Syndrome

Prone Positioning and R/I Ratio in COVID-19 Patients With ARDS (SyDRAC-DV)

SyDRAC-DV
Start date: November 3, 2022
Phase:
Study type: Observational

The purpose of this study is to determine the efects of prone positioning on the recruitment- to-inflation ratio in COVID-19 patients with acute respiratory distress syndrome.

NCT ID: NCT05360641 Completed - Clinical trials for Portal Vein Thrombosis

Risk Factors for Recurrence of Thrombosis or Thrombotic Extension, in the Event of Acute Non-cirrhotic Portal Vein Thrombosis Secondary to a Local Cause.

LOCAPORT
Start date: August 1, 2019
Phase:
Study type: Observational

In case of acute portal vein thrombosis (PVT) prothrombotic factors are identified in about 60% of cases, while a local condition is present in 30% of cases. Prothrombotic factors may indicate a long term anticoagulant therapy whereas the risk of recurrence seems low when a local condition is isolated (cholecystitis, angiocholitis, liver abces, diverticulitis, appendicitis, acute/chronic pancreatitis, chronic bowel inflammatory disease, acute hepatitis due to cytomegalovirus, bacteroïdes pylephlebitis, abdominal neoplasia such as adenocarcinoma of the colon, abdominal traumatism or surgery such as cholecystectomy, bariatric surgery or splenectomy). To date the impact of prothrombotic factors associated with local conditions responsible for acute PVT has not been well studied except for acute or chronic pancreatitis. No significant association has been pointed out in this pathology. The aim is to determine what are the risk factors of thrombotic recurrence or extension associated with local conditions responsible for acute non cirrhotic PVT, and to evaluate the rate of secondary long term anticoagulant therapy.